These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 30229466)
21. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? Jang WS; Kim MS; Jeong WS; Chang KD; Cho KS; Ham WS; Rha KH; Hong SJ; Choi YD BJU Int; 2018 Feb; 121(2):225-231. PubMed ID: 28834084 [TBL] [Abstract][Full Text] [Related]
22. Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective study. Kozal S; Peyronnet B; Cattarino S; Seisen T; Comperat E; Vaessen C; Mozer P; Renard-Penna R; Cussenot O; Rouprêt M; Drouin SJ Urol Oncol; 2015 Jul; 33(7):330.e1-7. PubMed ID: 25998747 [TBL] [Abstract][Full Text] [Related]
23. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? Punnen S; Meng MV; Cooperberg MR; Greene KL; Cowan JE; Carroll PR BJU Int; 2013 Aug; 112(4):E314-20. PubMed ID: 23451984 [TBL] [Abstract][Full Text] [Related]
24. Technical Refinements in Superextended Robot-assisted Radical Prostatectomy for Locally Advanced Prostate Cancer Patients at Multiparametric Magnetic Resonance Imaging. Mazzone E; Dell'Oglio P; Rosiello G; Puliatti S; Brook N; Turri F; Larcher A; Beato S; Andras I; Wisz P; Pandey A; De Groote R; Schatteman P; De Naeyer G; D'Hondt F; Mottrie A Eur Urol; 2021 Jul; 80(1):104-112. PubMed ID: 32943260 [TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis. Matsumoto T; Hatakeyama S; Ookubo T; Mitsuzuka K; Narita S; Inoue T; Yamashita S; Narita T; Koie T; Kawamura S; Tochigi T; Tsuchiya N; Habuchi T; Arai Y; Ohyama C Med Oncol; 2017 Oct; 34(12):190. PubMed ID: 29090390 [TBL] [Abstract][Full Text] [Related]
26. Oncologic outcomes at 10 years following robotic radical prostatectomy. Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687 [TBL] [Abstract][Full Text] [Related]
27. Number of positive preoperative biopsy cores is a predictor of positive surgical margins (PSM) in small prostates after robot-assisted radical prostatectomy (RARP). Tuliao PH; Koo KC; Komninos C; Chang CH; Choi YD; Chung BH; Hong SJ; Rha KH BJU Int; 2015 Dec; 116(6):897-904. PubMed ID: 25098818 [TBL] [Abstract][Full Text] [Related]
28. Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis. Wang L; Wang B; Ai Q; Zhang Y; Lv X; Li H; Ma X; Zhang X Int Urol Nephrol; 2017 Jun; 49(6):995-1005. PubMed ID: 28238148 [TBL] [Abstract][Full Text] [Related]
29. [Propensity score comparison of the various radical surgical techniques for high-risk prostate cancer]. Busch J; Gonzalgo M; Leva N; Ferrari M; Friedersdorff F; Hinz S; Kempkensteffen C; Miller K; Magheli A Aktuelle Urol; 2015 Jan; 46(1):45-51. PubMed ID: 25526221 [TBL] [Abstract][Full Text] [Related]
30. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control. Hu JC; Gandaglia G; Karakiewicz PI; Nguyen PL; Trinh QD; Shih YC; Abdollah F; Chamie K; Wright JL; Ganz PA; Sun M Eur Urol; 2014 Oct; 66(4):666-72. PubMed ID: 24602934 [TBL] [Abstract][Full Text] [Related]
31. Predicting the risk of positive surgical margins following robotic-assisted radical prostatectomy. Alchin DR; Murphy D; Lawrentschuk N Minerva Urol Nefrol; 2017 Feb; 69(1):56-62. PubMed ID: 28009145 [TBL] [Abstract][Full Text] [Related]
32. Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis. Noda M; Taguchi S; Shiraishi K; Fujimura T; Naito A; Kawai T; Kamei J; Akiyama Y; Yamada Y; Sato Y; Yamada D; Nakagawa T; Yamashita H; Nakagawa K; Abe O; Fukuhara H; Kume H Strahlenther Onkol; 2024 Aug; 200(8):676-683. PubMed ID: 38180494 [TBL] [Abstract][Full Text] [Related]
33. Impact of a preoperatively estimated prostate volume using transrectal ultrasonography on surgical and oncological outcomes in a single surgeon's experience with robot-assisted radical prostatectomy. Hirasawa Y; Ohno Y; Nakashima J; Shimodaira K; Hashimoto T; Gondo T; Ohori M; Tachibana M; Yoshioka K Surg Endosc; 2016 Sep; 30(9):3702-8. PubMed ID: 26578435 [TBL] [Abstract][Full Text] [Related]
35. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [TBL] [Abstract][Full Text] [Related]
36. Patterns-of-care and health economic analysis of robot-assisted radical prostatectomy in the Australian public health system. Basto M; Sathianathen N; Te Marvelde L; Ryan S; Goad J; Lawrentschuk N; Costello AJ; Moon DA; Heriot AG; Butler J; Murphy DG BJU Int; 2016 Jun; 117(6):930-9. PubMed ID: 26350758 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801 [TBL] [Abstract][Full Text] [Related]
39. Comparative analysis of oncologic outcomes for open vs. robot-assisted radical prostatectomy in high-risk prostate cancer. Lee D; Choi SK; Park J; Shim M; Kim A; Lee S; Song C; Ahn H Korean J Urol; 2015 Aug; 56(8):572-9. PubMed ID: 26279826 [TBL] [Abstract][Full Text] [Related]
40. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis. Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Aoki M; Takai Y World J Surg Oncol; 2014 Apr; 12():134. PubMed ID: 24885947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]